605 related articles for article (PubMed ID: 11713766)
1. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
3. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
Kagawa S; Fujiwara T; Tanaka N
Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
[TBL] [Abstract][Full Text] [Related]
6. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
7. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
8. [Adenoviral p53 gene therapy for human lung cancer].
Fujiwara T; Tanaka N
Gan To Kagaku Ryoho; 2003 Apr; 30(4):460-7. PubMed ID: 12722675
[TBL] [Abstract][Full Text] [Related]
9. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
[TBL] [Abstract][Full Text] [Related]
10. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Heise C; Lemmon M; Kirn D
Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.
Wang WD; Li R; Chen ZT; Li DZ; Duan YZ; Cao ZH
Cancer Sci; 2005 Oct; 96(10):706-12. PubMed ID: 16232203
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
Nielsen LL
Oncol Rep; 2000; 7(6):1191-6. PubMed ID: 11032912
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
[TBL] [Abstract][Full Text] [Related]
15. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region.
Edelman J; Edelman J; Nemunaitis J
Curr Opin Mol Ther; 2003 Dec; 5(6):611-7. PubMed ID: 14755887
[TBL] [Abstract][Full Text] [Related]
18. New horizons: gene therapy for cancer.
Baselga J
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S39-42. PubMed ID: 10630368
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
[TBL] [Abstract][Full Text] [Related]
20. Restoration of tumour suppressor gene expression for cancer.
Roth JA
Forum (Genova); 1998; 8(4):368-76. PubMed ID: 9863031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]